Breaking News

Cedarburg Hauser Site Granted DEA Registration

February 27, 2013

Denver facility can manufacture schedule II-V controlled substances

Cedarburg Hauser’s Denver, CO facility has been granted registration as a manufacturer of schedule II-V controlled substances by the U.S Drug Enforcement Agency (DEA). The new DEA registration status allows the company to manufacture controlled substances and provides additional capacity when added to its existing controlled substance manufacturing capabilities at its Grafton, WI facility.
 
"The GMP manufacturing and analytical method development expertise of Cedarburg Hauser's Denver facility may now be extended to DEA scheduled compounds," said vice president and general manager, Joe Guiles. "This further emphasizes these competencies, and represents an opportunity to expand our customer base and serve the needs of our existing customers."
 
"The development and manufacturing of controlled substances requires stringent controls and security measures," said Dan Childers, vice president of Quality Assurance and Regulatory Compliance. "DEA registration further illustrates the strength of the manufacturing, handling and storage controls in place at Cedarburg Hauser's Denver facility."

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks